Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Am Board Fam Med ; 36(6): 1050-1057, 2024 Jan 05.
Article in English | MEDLINE | ID: mdl-37857441

ABSTRACT

BACKGROUND: Physician departure causes considerable disruption for patients, colleagues, and staff. The cost of finding a new physician to replace the loss coupled with lost productivity as they build their practice can cost as much as $1 million per departure. Therefore, we sought to characterize drivers of departure from practice with the goal of informing retention efforts (with a special emphasis on the connection between electronic health record (EHR)-related stress and physician departure). METHODS: This qualitative study of semistructured interviews was conducted between October 2021 and April 2022 among 13 attending physicians who had voluntarily departed their position from 2018 to 2021 in a large multispecialty, productivity-based, ambulatory practice network in the Northeast with a 5% annual turnover rate to understand their reasons for departing practice. RESULTS: Among the 13 participants, 8 were women (61.5%), 3 retired (23.1%), and 6 (46.2%) left for new positions. Major domains surrounding the decision to depart included current features of the health care delivery landscape, leadership/local practice culture, and personal considerations. Major factors within these domains included the EHR, compensation model, emphasis on metrics, leadership support, teamwork/staffing, burnout, and work-life integration. CONCLUSIONS: Opportunities for medical practices to prevent ambulatory physicians' turnover include: (1) addressing workflow by distributing responsibility across team members to better address patient expectations and documentation requirements, (2) ensuring adequate staffing across disciplines and roles, and (3) considering alternative care or payment models.


Subject(s)
Burnout, Professional , Physicians , Humans , Female , Male , Delivery of Health Care , Burnout, Professional/prevention & control , Workforce , Qualitative Research , Electronic Health Records
2.
JAMA Netw Open ; 4(3): e214149, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33739434

ABSTRACT

Importance: Significant concern has been raised that crisis standards of care policies aimed at guiding resource allocation may be biased against people based on race/ethnicity. Objective: To evaluate whether unanticipated disparities by race or ethnicity arise from a single institution's resource allocation policy. Design, Setting, and Participants: This cohort study included adults (aged ≥18 years) who were cared for on a coronavirus disease 2019 (COVID-19) ward or in a monitored unit requiring invasive or noninvasive ventilation or high-flow nasal cannula between May 26 and July 14, 2020, at 2 academic hospitals in Miami, Florida. Exposures: Race (ie, White, Black, Asian, multiracial) and ethnicity (ie, non-Hispanic, Hispanic). Main Outcomes and Measures: The primary outcome was based on a resource allocation priority score (range, 1-8, with 1 indicating highest and 8 indicating lowest priority) that was assigned daily based on both estimated short-term (using Sequential Organ Failure Assessment score) and longer-term (using comorbidities) mortality. There were 2 coprimary outcomes: maximum and minimum score for each patient over all eligible patient-days. Standard summary statistics were used to describe the cohort, and multivariable Poisson regression was used to identify associations of race and ethnicity with each outcome. Results: The cohort consisted of 5613 patient-days of data from 1127 patients (median [interquartile range {IQR}] age, 62.7 [51.7-73.7]; 607 [53.9%] men). Of these, 711 (63.1%) were White patients, 323 (28.7%) were Black patients, 8 (0.7%) were Asian patients, and 31 (2.8%) were multiracial patients; 480 (42.6%) were non-Hispanic patients, and 611 (54.2%) were Hispanic patients. The median (IQR) maximum priority score for the cohort was 3 (1-4); the median (IQR) minimum score was 2 (1-3). After adjustment, there was no association of race with maximum priority score using White patients as the reference group (Black patients: incidence rate ratio [IRR], 1.00; 95% CI, 0.89-1.12; Asian patients: IRR, 0.95; 95% CI. 0.62-1.45; multiracial patients: IRR, 0.93; 95% CI, 0.72-1.19) or of ethnicity using non-Hispanic patients as the reference group (Hispanic patients: IRR, 0.98; 95% CI, 0.88-1.10); similarly, no association was found with minimum score for race, again with White patients as the reference group (Black patients: IRR, 1.01; 95% CI, 0.90-1.14; Asian patients: IRR, 0.96; 95% CI, 0.62-1.49; multiracial patients: IRR, 0.81; 95% CI, 0.61-1.07) or ethnicity, again with non-Hispanic patients as the reference group (Hispanic patients: IRR, 1.00; 95% CI, 0.89-1.13). Conclusions and Relevance: In this cohort study of adult patients admitted to a COVID-19 unit at 2 US hospitals, there was no association of race or ethnicity with the priority score underpinning the resource allocation policy. Despite this finding, any policy to guide altered standards of care during a crisis should be monitored to ensure equitable distribution of resources.


Subject(s)
COVID-19 , Health Care Rationing , Healthcare Disparities/ethnology , Hospitalization/statistics & numerical data , Resource Allocation , Standard of Care/statistics & numerical data , COVID-19/ethnology , COVID-19/therapy , Cohort Studies , Ethnicity , Female , Florida/epidemiology , Health Care Rationing/methods , Health Care Rationing/organization & administration , Health Services Needs and Demand , Humans , Male , Middle Aged , Mortality/ethnology , Resource Allocation/methods , Resource Allocation/organization & administration
3.
BMC Infect Dis ; 20(1): 964, 2020 Dec 22.
Article in English | MEDLINE | ID: mdl-33353546

ABSTRACT

BACKGROUND: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2. METHODS: A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. RESULTS: Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1-21) after initial symptoms and 2 days (range 0-12) after hospital admission. Within 30 days from receiving tocilizumab, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. After tocilizumab was administered, there was a slight increase in PaO2/FiO2 and an initial reduction in CRP, but this effect was not sustained beyond day 10. CONCLUSIONS: Majority of patients demonstrated clinical improvement and were successfully discharged alive from the hospital after receiving tocilizumab. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the early treatment of COVID-19, however larger randomized controlled studies are needed to confirm this.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , COVID-19 Drug Treatment , Receptors, Interleukin-6/antagonists & inhibitors , Respiratory Insufficiency/drug therapy , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized/pharmacology , COVID-19/complications , Cohort Studies , Female , Hospitalization , Humans , Male , Middle Aged , Respiratory Insufficiency/virology , Retrospective Studies , SARS-CoV-2 , Treatment Outcome
4.
AIDS Behav ; 24(1): 246-256, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31555932

ABSTRACT

Prevention of HIV outbreaks among people who inject drugs remains a challenge to ending the HIV epidemic in the United States. The first legal syringe services program (SSP) in Florida implemented routine screening in 2018 leading to the identification of ten anonymous HIV seroconversions. The SSP collaborated with the Department of Health to conduct an epidemiologic investigation. All seven acute HIV seroconversions were linked to care (86% within 30 days) and achieved viral suppression (mean 70 days). Six of the seven individuals are epidemiologically and/or socially linked to at least two other seroconversions. Analysis of the HIV genotypes revealed that two individuals are connected molecularly at 0.5% genetic distance. We identified a risk network with complex transmission dynamics that could not be explained by epidemiological methods or molecular analyses alone. Providing wrap-around services through the SSP, including routine screening, intensive linkage and patient navigation, could be an effective model for achieving viral suppression for people who inject drugs.


Subject(s)
Disease Outbreaks/prevention & control , HIV Infections/prevention & control , Risk-Taking , Substance Abuse, Intravenous/complications , Adult , Aged , Female , Florida/epidemiology , Humans , Male , Middle Aged , Sexual and Gender Minorities , Substance Abuse, Intravenous/epidemiology , United States
5.
N Y State Dent J ; 79(5): 40-4, 2013.
Article in English | MEDLINE | ID: mdl-24245461

ABSTRACT

This article describes a clinical case involving a unique solution to restoring implants placed in an unfavorable, labial location in the anterior maxilla. Background information is provided with regard to avoiding compromised situations from the outset, as well as a discussion of issues of restorability, with an emphasis on dental implants. Different treatment options are explored. To complete the case presented, a custom cast framework resembling traditional veneer preparations was selected, with porcelain veneers to cover abutment screw access channels.


Subject(s)
Dental Arch/surgery , Dental Implants , Dental Prosthesis, Implant-Supported , Denture Design , Denture, Partial, Fixed , Maxilla/surgery , Aged , Cementation/methods , Composite Resins/chemistry , Dental Implant-Abutment Design , Dental Materials/chemistry , Dental Porcelain/chemistry , Dental Veneers , Humans , Male , Patient Care Planning
SELECTION OF CITATIONS
SEARCH DETAIL
...